TY - JOUR
T1 - Benzimidazole based Pt(II) complexes with better normal cell viability than cisplatin
T2 - Synthesis, substitution behavior, cytotoxicity, DNA binding and DFT study
AU - Mitra, Ishani
AU - Mukherjee, Subhajit
AU - Reddy Venkata, P. B.
AU - Dasgupta, Subrata
AU - Jagadeesh Bose, C. K.
AU - Mukherjee, Sandip
AU - Linert, Wolfgang
AU - Moi, Sankar Ch
N1 - Publisher Copyright:
© The Royal Society of Chemistry 2016.
PY - 2016
Y1 - 2016
N2 - cis-[Pt(ambim)Cl2] 1 (where, ambim = 2-aminomethylbenzimidazole) has been synthesized and characterized by spectroscopic methods. Reaction kinetics between the hydrolyzed product, cis-[Pt(ambim)(H2O)2]2+2 with dl-penicillamine (dl-pen) and glutathione (GSH) have been studied spectrophotometrically in aqueous medium. At pH 4.0, the interactions of 2 with the ligands show two distinct consecutive steps. The association equilibrium constant (KE) for the outer sphere complex formation and rate constants for both the steps have been evaluated. Activation parameters (ΔH‡ and ΔS‡) were evaluated using the Eyring equation and an associative mechanism is proposed for both the reactions. Computational studies using Density Functional Theory (DFT) were carried out to investigate the electronic structures of the complexes. To study the nature of the electronic transitions in complex 1, time dependent DFT was performed. The DNA binding properties of the complexes 2-4 were evaluated by spectroscopic titration, fluorescence indicator displacement experiments and electrophoresis measurements. The complexes effectively bind to calf-thymus DNA via different binding modes with intrinsic binding constants (Kb) in the range of 2.22 × 104 to 4.76 × 104 M-1 which was supported by molecular docking studies. The antiproliferative properties of 2-4 were probed in vitro against human cervical cancer, non-small cell lung carcinoma and hepatocellular liver carcinoma cell lines and 2 was found to be most effective in growth inhibition in all the cell lines. Remarkably, the complexes also generate lower levels of reactive oxygen species (ROS) than cisplatin and have almost no adverse effects on normal cells.
AB - cis-[Pt(ambim)Cl2] 1 (where, ambim = 2-aminomethylbenzimidazole) has been synthesized and characterized by spectroscopic methods. Reaction kinetics between the hydrolyzed product, cis-[Pt(ambim)(H2O)2]2+2 with dl-penicillamine (dl-pen) and glutathione (GSH) have been studied spectrophotometrically in aqueous medium. At pH 4.0, the interactions of 2 with the ligands show two distinct consecutive steps. The association equilibrium constant (KE) for the outer sphere complex formation and rate constants for both the steps have been evaluated. Activation parameters (ΔH‡ and ΔS‡) were evaluated using the Eyring equation and an associative mechanism is proposed for both the reactions. Computational studies using Density Functional Theory (DFT) were carried out to investigate the electronic structures of the complexes. To study the nature of the electronic transitions in complex 1, time dependent DFT was performed. The DNA binding properties of the complexes 2-4 were evaluated by spectroscopic titration, fluorescence indicator displacement experiments and electrophoresis measurements. The complexes effectively bind to calf-thymus DNA via different binding modes with intrinsic binding constants (Kb) in the range of 2.22 × 104 to 4.76 × 104 M-1 which was supported by molecular docking studies. The antiproliferative properties of 2-4 were probed in vitro against human cervical cancer, non-small cell lung carcinoma and hepatocellular liver carcinoma cell lines and 2 was found to be most effective in growth inhibition in all the cell lines. Remarkably, the complexes also generate lower levels of reactive oxygen species (ROS) than cisplatin and have almost no adverse effects on normal cells.
UR - http://www.scopus.com/inward/record.url?scp=84983364755&partnerID=8YFLogxK
U2 - 10.1039/c6ra17788c
DO - 10.1039/c6ra17788c
M3 - Article
AN - SCOPUS:84983364755
SN - 2046-2069
VL - 6
SP - 76600
EP - 76613
JO - RSC Advances
JF - RSC Advances
IS - 80
ER -